📣 VC round data is live. Check it out!
- Public Comps
- Shandong Weigao Blood
Shandong Weigao Blood Valuation Multiples
Discover revenue and EBITDA valuation multiples for Shandong Weigao Blood and similar public comparables like Dentsply Sirona, Inner Mongolia Furui Medical Science, Chengzhi, Ansell and more.
Shandong Weigao Blood Overview
About Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
Founded
2004
HQ

Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialShandong Weigao Blood Financials
Shandong Weigao Blood reported last 12-month revenue of $566M and EBITDA of $121M.
In the same LTM period, Shandong Weigao Blood generated $227M in gross profit, $121M in EBITDA, and $71M in net income.
Revenue (LTM)
Shandong Weigao Blood P&L
In the most recent fiscal year, Shandong Weigao Blood reported revenue of $555M and EBITDA of $121M.
Shandong Weigao Blood is profitable as of last fiscal year, with gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Shandong Weigao Blood Stock Performance
Shandong Weigao Blood has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Shandong Weigao Blood's stock price is $5.02.
Shandong Weigao Blood share price decreased by 4.5% in the last 30 days, and by 5.5% in the last year.
Shandong Weigao Blood has an EPS (earnings per share) of $0.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -3.2% | -4.5% | -15.6% | -5.5% | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShandong Weigao Blood Valuation Multiples
Shandong Weigao Blood trades at 3.0x EV/Revenue multiple, and 13.9x EV/EBITDA.
EV / Revenue (LTM)
Shandong Weigao Blood Financial Valuation Multiples
As of May 27, 2026, Shandong Weigao Blood has market cap of $2B and EV of $2B.
Shandong Weigao Blood has a P/E ratio of 29.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shandong Weigao Blood Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Shandong Weigao Blood Margins & Growth Rates
Shandong Weigao Blood grew revenue by 8% and EBITDA by 1% in the last fiscal year.
In the most recent fiscal year, Shandong Weigao Blood reported gross margin of 40%, EBITDA margin of 22%, and net margin of 13%.
Shandong Weigao Blood Margins
Shandong Weigao Blood Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Shandong Weigao Blood Operational KPIs
Shandong Weigao Blood's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shandong Weigao Blood's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Shandong Weigao Blood Competitors
Shandong Weigao Blood competitors include Dentsply Sirona, Inner Mongolia Furui Medical Science, Chengzhi, Ansell, Kestra Medical Technologies, Haemonetics, Schott Pharma, Shinva, BioLife Solutions and Sopharma.
Most Shandong Weigao Blood public comparables operate across Medical Supplies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 1.1x | 6.3x | 6.5x | |||
| 8.3x | 7.5x | 29.1x | 30.6x | |||
| 1.3x | - | 16.2x | - | |||
| 1.6x | 1.6x | 9.2x | 8.5x | |||
| 17.0x | 10.6x | (12.8x) | (12.2x) | |||
| 3.0x | 2.9x | 10.0x | 9.9x | |||
| 2.6x | 2.6x | 9.1x | 9.5x | |||
| 0.6x | 0.6x | 7.1x | 7.0x | |||
This data is available for Pro users. Sign up to see all Shandong Weigao Blood competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shandong Weigao Blood
| When was Shandong Weigao Blood founded? | Shandong Weigao Blood was founded in 2004. |
| Where is Shandong Weigao Blood headquartered? | Shandong Weigao Blood is headquartered in China. |
| Is Shandong Weigao Blood publicly listed? | Yes, Shandong Weigao Blood is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Shandong Weigao Blood? | Shandong Weigao Blood trades under 603014 ticker. |
| When did Shandong Weigao Blood go public? | Shandong Weigao Blood went public in 2025. |
| Who are competitors of Shandong Weigao Blood? | Shandong Weigao Blood main competitors include Dentsply Sirona, Inner Mongolia Furui Medical Science, Chengzhi, Ansell, Kestra Medical Technologies, Haemonetics, Schott Pharma, Shinva, BioLife Solutions, Sopharma. |
| What is the current market cap of Shandong Weigao Blood? | Shandong Weigao Blood's current market cap is $2B. |
| What is the current revenue of Shandong Weigao Blood? | Shandong Weigao Blood's last 12 months revenue is $566M. |
| What is the current revenue growth of Shandong Weigao Blood? | Shandong Weigao Blood revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Shandong Weigao Blood? | Current revenue multiple of Shandong Weigao Blood is 3.0x. |
| What is the current EBITDA of Shandong Weigao Blood? | Shandong Weigao Blood's last 12 months EBITDA is $121M. |
| What is Shandong Weigao Blood's EBITDA margin? | Shandong Weigao Blood's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Shandong Weigao Blood? | Current EBITDA multiple of Shandong Weigao Blood is 13.9x. |
| How many companies Shandong Weigao Blood has acquired to date? | Shandong Weigao Blood hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Shandong Weigao Blood has invested to date? | Shandong Weigao Blood hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Shandong Weigao Blood
Lists including Shandong Weigao Blood
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.